DGIdb - MAPK10 Gene Record

MAPK10 5602 Druggable Genome

Alternate Names:

5602
MITOGEN-ACTIVATED PROTEIN KINASE 10
MAPK10
JNK3
JNK3A
PRKM10
SAPK1b
p493F12
p54bSAPK
602897
6872
ENSG00000109339
OTTHUMG00000130604
P53779
MK10_HUMAN
MAPK 10
MAP kinase 10
c-Jun N-terminal kinase 3
Stress-activated protein kinase JNK3
Stress-activated protein kinase 1b
MAP kinase p49 3F12
PA30617
1498
BE0001097
MITOGEN-ACTIVATED PROTEIN KINASE 10 (EC 2.7.1.37) (STRESS-ACTIVATED PROTEIN KINASE JNK3) (C-JUN N-TERMINAL KINASE 3) (MAP KINASE P49 3F12). [SOURCE:UNIPROT/SWISSPROT;ACC:P53779]
NP_002744
NM_002753
T00663
BE0009865

Gene Info:

Human Readable Name	SERINE THREONINE KINASE
Interpro Short Name	Ser/Thr_dual-sp_kinase_dom
Uniprot Status	Swiss-Prot
Interpro Name	Serine/threonine- / dual-specificity protein kinase, catalytic domain
Uniprot Evidence	1: Evidence at protein level
Human Readable Name	DRUGGABLE GENOME
Interpro Acc	IPR002290
Interpro Type	Domain
Human Readable Name	KINASE
Has Variant Annotation	false
Is VIP	false
Target Class	Enzymes
Target Subclass	EC:2.7.11.24
GuideToPharmacology Gene Type	enzyme
GuideToPharmacology Gene Category Name	JNK subfamily
GuideToPharmacology Gene Category ID	518
Gene Biotype	PROTEIN_CODING

(13 More Sources)

Gene Categories: Category Details

KINASE
SERINE THREONINE KINASE
DRUGGABLE GENOME
ENZYME
TRANSCRIPTION FACTOR

Publications:

Selig R et al., 2012, A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors., J Med Chem
Nakajima et al., 2006, Differential roles of MAP kinases in atorvastatin-induced VEGF release in cardiac myocytes., Life Sci.
Hupfeld et al., 2003, Beta -Arrestin 1 down-regulation after insulin treatment is associated with supersensitization of beta 2 adrenergic receptor Galpha s signaling in 3T3-L1 adipocytes., Proc. Natl. Acad. Sci. U.S.A.
Alblas et al., 1998, The role of MAP kinase in TPA-mediated cell cycle arrest of human breast cancer cells., Oncogene
Paine et al., 2000, Arachidonic acid activates mitogen-activated protein (MAP) kinase-activated protein kinase 2 and mediates adhesion of a human breast carcinoma cell line to collagen type IV through a p38 MAP kinase-dependent pathway., J. Biol. Chem.
Duncan et al., 2005, Signal transduction pathways leading to increased eIF4E phosphorylation caused by oxidative stress., Free Radic. Biol. Med.
Kim MH et al., 2013, Syntheses and biological evaluation of 1-heteroaryl-2-aryl-1H-benzimidazole derivatives as c-Jun N-terminal kinase inhibitors with neuroprotective effects., Bioorg Med Chem
Manuvakhova et al., 2006, Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells., Oncogene
Bowen et al., 2007, Irinotecan changes gene expression in the small intestine of the rat with breast cancer., Cancer Chemother. Pharmacol.
Flynn et al., 1996, Insulin-stimulated phosphorylation of initiation factor 4E is mediated by the MAP kinase pathway., FEBS Lett.
Bamborough et al., 2008, Assessment of chemical coverage of kinome space and its implications for kinase drug discovery., J. Med. Chem.
Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics
Saeed et al., 2004, Signaling mechanisms mediated by G-protein coupled receptors in human platelets., Acta Pharmacol. Sin.
Jang S et al., 2015, Critical role of c-jun N-terminal protein kinase in promoting mitochondrial dysfunction and acute liver injury., Redox Biol
Augustine C et al., 2014, Traumatic injury elicits JNK-mediated human astrocyte retraction in vitro., Neuroscience
Jang S et al., 2014, Inhibition of JNK aggravates the recovery of rat hearts after global ischemia: the role of mitochondrial JNK., PLoS One
Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect

BRIMAPITIDE MAPK10

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

Publications:
BENTAMAPIMOD MAPK10

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction c-Jun N-terminal kinase, JNK inhibitor

Direct Interaction yes

Publications:
CC-401 MAPK10

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction c-Jun N-terminal kinase 3 inhibitor

Publications:
TANZISERTIB MAPK10

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Publications:
PAMAPIMOD MAPK10

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Details of the Assay for Interaction In a biochemical assay.

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Publications:
HESPERADIN MAPK10

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Bamborough et al., 2008, Assessment of chemical coverage of kinome space and its implications for kinase drug discovery., J. Med. Chem.

HALICIN MAPK10

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Jang S et al., 2015, Critical role of c-jun N-terminal protein kinase in promoting mitochondrial dysfunction and acute liver injury., Redox Biol

Augustine C et al., 2014, Traumatic injury elicits JNK-mediated human astrocyte retraction in vitro., Neuroscience

Jang S et al., 2014, Inhibition of JNK aggravates the recovery of rat hearts after global ischemia: the role of mitochondrial JNK., PLoS One

FOSTAMATINIB MAPK10

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect
BRIMAPITIDE, C-TERMINAL ACID MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name AM-111

Novel drug target Novel Target

Publications:
SB-202190 MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Selig R et al., 2012, A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors., J Med Chem
ATORVASTATIN MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Nakajima et al., 2006, Differential roles of MAP kinases in atorvastatin-induced VEGF release in cardiac myocytes., Life Sci.

ISOPROTERENOL MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Hupfeld et al., 2003, Beta -Arrestin 1 down-regulation after insulin treatment is associated with supersensitization of beta 2 adrenergic receptor Galpha s signaling in 3T3-L1 adipocytes., Proc. Natl. Acad. Sci. U.S.A.

chembl:CHEMBL35482 MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Alblas et al., 1998, The role of MAP kinase in TPA-mediated cell cycle arrest of human breast cancer cells., Oncogene

Paine et al., 2000, Arachidonic acid activates mitogen-activated protein (MAP) kinase-activated protein kinase 2 and mediates adhesion of a human breast carcinoma cell line to collagen type IV through a p38 MAP kinase-dependent pathway., J. Biol. Chem.

WORTMANNIN MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Duncan et al., 2005, Signal transduction pathways leading to increased eIF4E phosphorylation caused by oxidative stress., Free Radic. Biol. Med.

SP-600125 MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kim MH et al., 2013, Syntheses and biological evaluation of 1-heteroaryl-2-aryl-1H-benzimidazole derivatives as c-Jun N-terminal kinase inhibitors with neuroprotective effects., Bioorg Med Chem

FIBROBLAST GROWTH FACTOR-1 MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Manuvakhova et al., 2006, Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells., Oncogene

IRINOTECAN MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Bowen et al., 2007, Irinotecan changes gene expression in the small intestine of the rat with breast cancer., Cancer Chemother. Pharmacol.
INSULIN MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Flynn et al., 1996, Insulin-stimulated phosphorylation of initiation factor 4E is mediated by the MAP kinase pathway., FEBS Lett.
SIROLIMUS MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Duncan et al., 2005, Signal transduction pathways leading to increased eIF4E phosphorylation caused by oxidative stress., Free Radic. Biol. Med.
SORAFENIB MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics
EPINEPHRINE MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Saeed et al., 2004, Signaling mechanisms mediated by G-protein coupled receptors in human platelets., Acta Pharmacol. Sin.
DORAMAPIMOD MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
chembl:CHEMBL280099 MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
chembl:CHEMBL406845 MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
AST-487 MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
JNJ-7706621 MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
SB-203580 MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
GEFITINIB MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
TOZASERTIB MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
DOVITINIB MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
chembl:CHEMBL191384 MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
IMATINIB MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
PF-00562271 MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
R-406 MAPK10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Ensembl: ENSG00000109339
- Version: 101_38
Alternate Names:

MAPK10 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TdgClinicalTrial: P53779
- Version: January-2014
Alternate Names:

MAPK10 Gene Symbol

Gene Info:

Target Class Enzymes

Target Subclass EC:2.7.11.24

Publications:

RussLampel: ENSG00000109339

Version: 26-July-2011

Alternate Names:

MAPK10 Display Id

ENSG00000109339 Ensembl Gene Id

MITOGEN-ACTIVATED PROTEIN KINASE 10 (EC 2.7.1.37) (STRESS-ACTIVATED PROTEIN KINASE JNK3) (C-JUN N-TERMINAL KINASE 3) (MAP KINASE P49 3F12). [SOURCE:UNIPROT/SWISSPROT;ACC:P53779] Description

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

GuideToPharmacologyGenes: 1498
- Version: 4-March-2015
Alternate Names:

mitogen-activated protein kinase 10 HUGO Gene Name

6872 HUGO Gene ID

MAPK10 Gene Symbol

Gene Info:

GuideToPharmacology Gene Type enzyme

GuideToPharmacology Gene Category Name JNK subfamily

GuideToPharmacology Gene Category ID 518

Gene Categories:

SERINE THREONINE KINASE, KINASE

Publications:
HopkinsGroom: P53779
- Version: 11-September-2012
Alternate Names:

MK10_HUMAN Uniprot Id

P53779 Uniprot Accession

5602 Entrez Gene Id

Gene Info:

Interpro Short Name Ser/Thr_dual-sp_kinase_dom

Uniprot Status Swiss-Prot

Interpro Name Serine/threonine- / dual-specificity protein kinase, catalytic domain

Gene Categories:

KINASE, DRUGGABLE GENOME

Publications:
PharmGKB: MAPK10
- Version: 18-August-2020
Alternate Names:

PA30617 PharmGKB ID

Gene Info:

Publications:

Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics

DrugBank: BE0001097

Version: 5.1.7

Alternate Names:

MAPK10 DrugBank Gene Name

P53779 UniProt Accession

5602 Entrez Gene Id

Gene Info:

Publications:

Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov

Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.

Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov

DrugBank: BE0009865

Version: 5.1.7

Alternate Names:

MAPK10 DrugBank Gene Name

P53779 UniProt Accession

5602 Entrez Gene Id

Gene Info:

Publications:

Jang S et al., 2014, Inhibition of JNK aggravates the recovery of rat hearts after global ischemia: the role of mitochondrial JNK., PLoS One

Augustine C et al., 2014, Traumatic injury elicits JNK-mediated human astrocyte retraction in vitro., Neuroscience

Jang S et al., 2015, Critical role of c-jun N-terminal protein kinase in promoting mitochondrial dysfunction and acute liver injury., Redox Biol

NCI: MAPK10

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Bowen et al., 2007, Irinotecan changes gene expression in the small intestine of the rat with breast cancer., Cancer Chemother. Pharmacol.

Duncan et al., 2005, Signal transduction pathways leading to increased eIF4E phosphorylation caused by oxidative stress., Free Radic. Biol. Med.

Pan et al., 2007, K252a prevents nigral dopaminergic cell death induced by 6-hydroxydopamine through inhibition of both mixed-lineage kinase 3/c-Jun NH2-terminal kinase 3 (JNK3) and apoptosis-inducing kinase 1/JNK3 signaling pathways., Mol. Pharmacol.

DTC: MAPK10

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Selig R et al., 2012, A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors., J Med Chem

Bamborough et al., 2008, Assessment of chemical coverage of kinome space and its implications for kinase drug discovery., J. Med. Chem.

Kim MH et al., 2013, Syntheses and biological evaluation of 1-heteroaryl-2-aryl-1H-benzimidazole derivatives as c-Jun N-terminal kinase inhibitors with neuroprotective effects., Bioorg Med Chem

HingoraniCasas: ENSG00000109339
- Version: 31-May-2017
Alternate Names:

ENSG00000109339 Gene Symbol

MAPK10 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
ChemblInteractions: JNK3
- Version: chembl_23
Alternate Names:

JNK3A GENE_SYMBOL

PRKM10 GENE_SYMBOL

SAPK1B GENE_SYMBOL

Gene Info:

Publications:
GuideToPharmacologyInteractions: ENSG00000109339
- Version: 20-July-2020
Alternate Names:

mitogen-activated protein kinase 10 GuideToPharmacology Name

P53779 UniProtKB ID

Gene Info:

Publications:
TTD: Stress-activated protein kinase JNK3
- Version: 2020.06.01
Alternate Names:

JNK3 TTD Gene Abbreviation

T00663 TTD Target ID

Gene Info:

Publications:
HumanProteinAtlas: MAPK10
- Version: 19.3
Alternate Names:

ENSG00000109339 Ensembl Gene ID

JNK3 Human Protein Atlas Gene Synonym

p493F12 Human Protein Atlas Gene Synonym

Gene Info:

Gene Categories:

ENZYME

Publications:
Pharos: MAPK10
- Version: 03-September-2020
Alternate Names:

Mitogen-activated protein kinase 10 Gene Name

P53779 UniProt ID

Gene Info:

Gene Categories:

KINASE, TRANSCRIPTION FACTOR

Publications:
dGene: MAPK10
- Version: 27-Jun-2013
Alternate Names:

5602 Gene ID

JNK3 dGene Synonym

JNK3A dGene Synonym

Gene Info:

Gene Categories:

SERINE THREONINE KINASE, KINASE

Publications:

Direct Interaction?	False
Endogenous Drug?	False
Specific Action of the Ligand	Inhibition

Mechanism of Interaction	c-Jun N-terminal kinase, JNK inhibitor
Direct Interaction	yes

Direct Interaction	yes
Mechanism of Interaction	c-Jun N-terminal kinase 3 inhibitor

Details of the Assay for Interaction	In a biochemical assay.
Specific Action of the Ligand	Inhibition
Endogenous Drug?	False

MAPK10	Display Id
ENSG00000109339	Ensembl Gene Id
MITOGEN-ACTIVATED PROTEIN KINASE 10 (EC 2.7.1.37) (STRESS-ACTIVATED PROTEIN KINASE JNK3) (C-JUN N-TERMINAL KINASE 3) (MAP KINASE P49 3F12). [SOURCE:UNIPROT/SWISSPROT;ACC:P53779]	Description

mitogen-activated protein kinase 10	HUGO Gene Name
6872	HUGO Gene ID
MAPK10	Gene Symbol

MK10_HUMAN	Uniprot Id
P53779	Uniprot Accession
5602	Entrez Gene Id

MAPK10	DrugBank Gene Name
P53779	UniProt Accession
5602	Entrez Gene Id

mitogen-activated protein kinase 10	GuideToPharmacology Name
P53779	UniProtKB ID

Mitogen-activated protein kinase 10	Gene Name
P53779	UniProt ID

Trial Name	AM-111
Novel drug target	Novel Target

MAPK10 Gene Record

MAPK10 5602 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Inhibition

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction c-Jun N-terminal kinase, JNK inhibitor Direct Interaction yes

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction c-Jun N-terminal kinase 3 inhibitor

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Details of the Assay for Interaction In a biochemical assay. Specific Action of the Ligand Inhibition Endogenous Drug? False

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Publications: Bamborough et al., 2008, Assessment of chemical coverage of kinome space and its implications for kinase drug discovery., J. Med. Chem.

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Publications: Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect

Interaction Types & Directionality: n/a

Interaction Info: Trial Name AM-111 Novel drug target Novel Target

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Selig R et al., 2012, A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors., J Med Chem

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Nakajima et al., 2006, Differential roles of MAP kinases in atorvastatin-induced VEGF release in cardiac myocytes., Life Sci.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Hupfeld et al., 2003, Beta -Arrestin 1 down-regulation after insulin treatment is associated with supersensitization of beta 2 adrenergic receptor Galpha s signaling in 3T3-L1 adipocytes., Proc. Natl. Acad. Sci. U.S.A.

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Duncan et al., 2005, Signal transduction pathways leading to increased eIF4E phosphorylation caused by oxidative stress., Free Radic. Biol. Med.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Kim MH et al., 2013, Syntheses and biological evaluation of 1-heteroaryl-2-aryl-1H-benzimidazole derivatives as c-Jun N-terminal kinase inhibitors with neuroprotective effects., Bioorg Med Chem

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Manuvakhova et al., 2006, Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells., Oncogene

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Bowen et al., 2007, Irinotecan changes gene expression in the small intestine of the rat with breast cancer., Cancer Chemother. Pharmacol.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Flynn et al., 1996, Insulin-stimulated phosphorylation of initiation factor 4E is mediated by the MAP kinase pathway., FEBS Lett.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Duncan et al., 2005, Signal transduction pathways leading to increased eIF4E phosphorylation caused by oxidative stress., Free Radic. Biol. Med.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Saeed et al., 2004, Signaling mechanisms mediated by G-protein coupled receptors in human platelets., Acta Pharmacol. Sin.

Interaction Types & Directionality: n/a

Interaction Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction c-Jun N-terminal kinase, JNK inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction c-Jun N-terminal kinase 3 inhibitor

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Details of the Assay for Interaction In a biochemical assay.

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Interaction Types & Directionality:

inhibitor (inhibitory)

Publications:

Bamborough et al., 2008, Assessment of chemical coverage of kinome space and its implications for kinase drug discovery., J. Med. Chem.

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Types & Directionality:

inhibitor (inhibitory)

Publications:

Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name AM-111

Novel drug target Novel Target

Interaction Types & Directionality:

n/a

Publications:

Selig R et al., 2012, A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors., J Med Chem

Interaction Types & Directionality:

n/a

Publications:

Nakajima et al., 2006, Differential roles of MAP kinases in atorvastatin-induced VEGF release in cardiac myocytes., Life Sci.

Interaction Types & Directionality:

n/a

Publications:

Hupfeld et al., 2003, Beta -Arrestin 1 down-regulation after insulin treatment is associated with supersensitization of beta 2 adrenergic receptor Galpha s signaling in 3T3-L1 adipocytes., Proc. Natl. Acad. Sci. U.S.A.

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Duncan et al., 2005, Signal transduction pathways leading to increased eIF4E phosphorylation caused by oxidative stress., Free Radic. Biol. Med.

Interaction Types & Directionality:

n/a

Publications:

Kim MH et al., 2013, Syntheses and biological evaluation of 1-heteroaryl-2-aryl-1H-benzimidazole derivatives as c-Jun N-terminal kinase inhibitors with neuroprotective effects., Bioorg Med Chem

Interaction Types & Directionality:

n/a

Publications:

Manuvakhova et al., 2006, Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells., Oncogene

Interaction Types & Directionality:

n/a

Publications:

Bowen et al., 2007, Irinotecan changes gene expression in the small intestine of the rat with breast cancer., Cancer Chemother. Pharmacol.

Interaction Types & Directionality:

n/a

Publications:

Flynn et al., 1996, Insulin-stimulated phosphorylation of initiation factor 4E is mediated by the MAP kinase pathway., FEBS Lett.

Interaction Types & Directionality:

n/a

Publications:

Duncan et al., 2005, Signal transduction pathways leading to increased eIF4E phosphorylation caused by oxidative stress., Free Radic. Biol. Med.

Interaction Types & Directionality:

n/a

Publications:

Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Saeed et al., 2004, Signaling mechanisms mediated by G-protein coupled receptors in human platelets., Acta Pharmacol. Sin.

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Alternate Names:

MAPK10 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Alternate Names:

MAPK10 Gene Symbol

Gene Info:

Target Class Enzymes

Target Subclass EC:2.7.11.24